Cite
Wang Y, Wach JY, Sheehan P, et al. Diversity-Oriented Synthesis as a Strategy for Fragment Evolution against GSK3β. ACS Med Chem Lett. 2016;7(9):852-6doi: 10.1021/acsmedchemlett.6b00230.
Wang, Y., Wach, J. Y., Sheehan, P., Zhong, C., Zhan, C., Harris, R., Almo, S. C., Bishop, J., Haggarty, S. J., Ramek, A., Berry, K. N., O'Herin, C., Koehler, A. N., Hung, A. W., & Young, D. W. (2016). Diversity-Oriented Synthesis as a Strategy for Fragment Evolution against GSK3β. ACS medicinal chemistry letters, 7(9), 852-6. https://doi.org/10.1021/acsmedchemlett.6b00230
Wang, Yikai, et al. "Diversity-Oriented Synthesis as a Strategy for Fragment Evolution against GSK3β." ACS medicinal chemistry letters vol. 7,9 (2016): 852-6. doi: https://doi.org/10.1021/acsmedchemlett.6b00230
Wang Y, Wach JY, Sheehan P, Zhong C, Zhan C, Harris R, Almo SC, Bishop J, Haggarty SJ, Ramek A, Berry KN, O'Herin C, Koehler AN, Hung AW, Young DW. Diversity-Oriented Synthesis as a Strategy for Fragment Evolution against GSK3β. ACS Med Chem Lett. 2016 Jul 14;7(9):852-6. doi: 10.1021/acsmedchemlett.6b00230. eCollection 2016 Sep 08. PMID: 27660690; PMCID: PMC5018862.
Copy
Download .nbib